JPS621952B2 - - Google Patents
Info
- Publication number
- JPS621952B2 JPS621952B2 JP56117870A JP11787081A JPS621952B2 JP S621952 B2 JPS621952 B2 JP S621952B2 JP 56117870 A JP56117870 A JP 56117870A JP 11787081 A JP11787081 A JP 11787081A JP S621952 B2 JPS621952 B2 JP S621952B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- trimethylpsoralen
- lower alkyl
- aminomethyl
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 23
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N furocoumarin Natural products C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 claims description 23
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000007858 starting material Substances 0.000 claims description 5
- FMHHVULEAZTJMA-UHFFFAOYSA-N trioxsalen Chemical compound CC1=CC(=O)OC2=C1C=C1C=C(C)OC1=C2C FMHHVULEAZTJMA-UHFFFAOYSA-N 0.000 claims description 5
- -1 alkyl psoralen Chemical compound 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000006698 hydrazinolysis reaction Methods 0.000 claims 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 230000036211 photosensitivity Effects 0.000 description 16
- 229960000850 trioxysalen Drugs 0.000 description 14
- 206010015150 Erythema Diseases 0.000 description 11
- 231100000321 erythema Toxicity 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000003504 photosensitizing agent Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 231100000053 low toxicity Toxicity 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 3
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000002165 photosensitisation Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000632319 Homo sapiens Septin-7 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 238000009193 PUVA therapy Methods 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102100027981 Septin-7 Human genes 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- WBIICVGYYRRURR-UHFFFAOYSA-N 3-(aminomethyl)-2,5,9-trimethylfuro[3,2-g]chromen-7-one Chemical compound O1C(=O)C=C(C)C2=C1C(C)=C1OC(C)=C(CN)C1=C2 WBIICVGYYRRURR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101150101537 Olah gene Proteins 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000157653 Psora Species 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- 238000003459 chloroalkylation reaction Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 229940018557 citraconic acid Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 208000017983 photosensitivity disease Diseases 0.000 description 1
- 231100000434 photosensitization Toxicity 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯ãããœã©ã¬ã³é¡ïŒpsoralensïŒãå
ååŠ
çæ³ãå ååŠçæ³ã§çšããããé«ããããå æå
æ§æŽ»æ§ãæããããœã©ã¬ã³é¡ã«é¢ãããã®ã§ã
ãã
çæ³ãå ååŠçæ³ã§çšããããé«ããããå æå
æ§æŽ»æ§ãæããããœã©ã¬ã³é¡ã«é¢ãããã®ã§ã
ãã
ããœã©ã¬ã³é¡ã¯ãç®èå
æåæ§è¬ç©ãšããŠãäŸ
ãã°çœæã®æ²»çã«é·å¹Žäœ¿ãããŠãããããããå±
æããã³ïŒãŸãã¯çµå£æäžããå ç·ç §å°ãè¡ãªã
ãšãã¡ã©ãã³ç£çãåºæ¿ãæ¥çŒãå¹æãããã
ãããããã€ãŠããããã¯ãã®ãŸãŸå粧åçšãšã
ãŠã䜿çšãããŠãããæè¿ãããœã©ã¬ã³é¡ã¯ä¹Ÿç¬
çã®å åŠçæ³ã«æå¹ã§ããããšãæããã«ããã
ãã®å Žåããããã¯æ£è ã«çµå£ãŸãã¯å±ææäžã
ããåŒç¶ãæ£è ã®ç®èã¯ãäŸãã°ããœã©ã©ã€ã
ïŒPsoralitïŒïŒç»é²åæšïŒè£ 眮äžã®ãããªãªå¶åŸ¡ã
ãã玫å€ç·ç §å°ãåãããæ¬çŸæ£ã®é«ã軜æžç
ã¯ããã®ããã«ããŠããããããã
ãã°çœæã®æ²»çã«é·å¹Žäœ¿ãããŠãããããããå±
æããã³ïŒãŸãã¯çµå£æäžããå ç·ç §å°ãè¡ãªã
ãšãã¡ã©ãã³ç£çãåºæ¿ãæ¥çŒãå¹æãããã
ãããããã€ãŠããããã¯ãã®ãŸãŸå粧åçšãšã
ãŠã䜿çšãããŠãããæè¿ãããœã©ã¬ã³é¡ã¯ä¹Ÿç¬
çã®å åŠçæ³ã«æå¹ã§ããããšãæããã«ããã
ãã®å Žåããããã¯æ£è ã«çµå£ãŸãã¯å±ææäžã
ããåŒç¶ãæ£è ã®ç®èã¯ãäŸãã°ããœã©ã©ã€ã
ïŒPsoralitïŒïŒç»é²åæšïŒè£ 眮äžã®ãããªãªå¶åŸ¡ã
ãã玫å€ç·ç §å°ãåãããæ¬çŸæ£ã®é«ã軜æžç
ã¯ããã®ããã«ããŠããããããã
ããœã©ã¬ã³é¡ããããã®çšéããã³ç®çã«æå¹
ãªã®ã¯ããããç §å°ã®éãç®èã«çŽ æãçããã
ãå¹åãæããããšãšå°ãªããšãéšåçã«ã¯é¢ä¿
ããããããœã©ã¬ã³é¡ã«ã¯ããŸããã®ä»ã®çšéã
ããããããã®çšéããã³æ ¹æ¬çåçãªãã³ã«ç
è«ã¯ãç±³åœç¹èš±ç¬¬4124598å·ã«éšåçã«æããã«
ãããŠããããŸãããããªããã°çš®ã ã®æ¢ååè¡
ç©ããåœæ¥è ã«ãšã€ãŠå ¬ç¥ã®ããšã§ããã
ãªã®ã¯ããããç §å°ã®éãç®èã«çŽ æãçããã
ãå¹åãæããããšãšå°ãªããšãéšåçã«ã¯é¢ä¿
ããããããœã©ã¬ã³é¡ã«ã¯ããŸããã®ä»ã®çšéã
ããããããã®çšéããã³æ ¹æ¬çåçãªãã³ã«ç
è«ã¯ãç±³åœç¹èš±ç¬¬4124598å·ã«éšåçã«æããã«
ãããŠããããŸãããããªããã°çš®ã ã®æ¢ååè¡
ç©ããåœæ¥è ã«ãšã€ãŠå ¬ç¥ã®ããšã§ããã
çš®ã
ã®ç®çã«ããœã©ã¬ã³é¡ãçšããŠçŽ«å€ç·ã®å¶
埡äžã«ããå ååŠçæ³ã®éèŠæ§ãé«ãŸãã«ã€ãã
é©åºŠã«æå¹ãªå æåæ§ãæããããœã©ã¬ã³é¡ã®å¿
èŠæ§ããã€ããæçœã«ãªã€ãŠãããéå°ãã€å±éº
æ§ãã玫å€ç·ç §å°ãŸãã¯è² è·ã®å¿ ç¶æ§ããå ãã
ããã«ã極倧å æåæ§ã¯äžã€ã®æçœãªè©äŸ¡åºæºã§
ãããããããªãããå ååŠçæ³éå§åã®é床ã«
é·ãæéããå ããããã«ãå æåæ§è¬ç©ã®å±æ
ãŸãã¯çµå£æäžåŸãå æåæ§ã®éãããªéå§ããŸ
ãéèŠã§ãããäŸãã°ç §å°ãããæéã®é ãããª
ãã«ã¯é©åœäžå¯èœã®ãããªå Žåã«ã¯ãé·æãªãã
延é·ãããå Žåããããå Žåã«ã¯éèŠåºŠã®åºæºãš
ãªããããããŠãå æåæ§ã®æ¥éãªäœçšçºçŸãé
ãããªæ¥µå€§åãªãã³ã«éãããªäœçšäœäžã¯ãå å
åŠçæ³ãšããæ¯èŒçæ°ãããŸãæ¥éã«æ¡å€§ããŠã
ãåéã®å¥œãŸããè©äŸ¡åºæºãšããŠãã§ã«ç¢ºç«ããŠ
ããããããã¯é«ã極倧å æåæ§æŽ»æ§ã®ã¿ãšãã
åŸæ¥éèŠèŠãããå¯äžã®è©äŸ¡åºæºãšæ¯èŒããŠãå
æ§ã«éèŠãªã®ã§ããã
埡äžã«ããå ååŠçæ³ã®éèŠæ§ãé«ãŸãã«ã€ãã
é©åºŠã«æå¹ãªå æåæ§ãæããããœã©ã¬ã³é¡ã®å¿
èŠæ§ããã€ããæçœã«ãªã€ãŠãããéå°ãã€å±éº
æ§ãã玫å€ç·ç §å°ãŸãã¯è² è·ã®å¿ ç¶æ§ããå ãã
ããã«ã極倧å æåæ§ã¯äžã€ã®æçœãªè©äŸ¡åºæºã§
ãããããããªãããå ååŠçæ³éå§åã®é床ã«
é·ãæéããå ããããã«ãå æåæ§è¬ç©ã®å±æ
ãŸãã¯çµå£æäžåŸãå æåæ§ã®éãããªéå§ããŸ
ãéèŠã§ãããäŸãã°ç §å°ãããæéã®é ãããª
ãã«ã¯é©åœäžå¯èœã®ãããªå Žåã«ã¯ãé·æãªãã
延é·ãããå Žåããããå Žåã«ã¯éèŠåºŠã®åºæºãš
ãªããããããŠãå æåæ§ã®æ¥éãªäœçšçºçŸãé
ãããªæ¥µå€§åãªãã³ã«éãããªäœçšäœäžã¯ãå å
åŠçæ³ãšããæ¯èŒçæ°ãããŸãæ¥éã«æ¡å€§ããŠã
ãåéã®å¥œãŸããè©äŸ¡åºæºãšããŠãã§ã«ç¢ºç«ããŠ
ããããããã¯é«ã極倧å æåæ§æŽ»æ§ã®ã¿ãšãã
åŸæ¥éèŠèŠãããå¯äžã®è©äŸ¡åºæºãšæ¯èŒããŠãå
æ§ã«éèŠãªã®ã§ããã
è¿å¹Žéçºããã4â²âã¢ããã¡ãã«âïŒïŒ5â²ïŒïŒ
âããªã¡ãã«ããœã©ã¬ã³ã¯ãé«æ§èœã®çµå£çå æ
åå掻æ§ã«ãã€ãŠç¹åŸŽã¥ããããŠããããã«èŠã
ãããé«åºŠã®æ¯æ§ã瀺ããã®ã§ããããã¡ããäœ
æ¯æ§ã¯éèŠãªããšã§ãããäžæ¹ãååç©5â²âã¢ã
ãã¡ãã«â4â²âã¡ãã«ããœã©ã¬ã³ããã³8â²âã¢ã
ãã¡ãã«ããœã©ã¬ã³ã¯ãïŒâã¡ãã«åºãæããªã
ããçŽ ææ§ã§ã¯æ¬è³ªçã«çµå£çã«ã¯äžæŽ»æ§ã§ã
ãããããæ¬çºæã®åéããã³é£æ¥åéã«ãã
ãŠãåŸæ¥ã§ã¯äºæ³ãããåŸãªãå æåæ§æŽ»æ§ã瀺
ããã®ã§ããã
âããªã¡ãã«ããœã©ã¬ã³ã¯ãé«æ§èœã®çµå£çå æ
åå掻æ§ã«ãã€ãŠç¹åŸŽã¥ããããŠããããã«èŠã
ãããé«åºŠã®æ¯æ§ã瀺ããã®ã§ããããã¡ããäœ
æ¯æ§ã¯éèŠãªããšã§ãããäžæ¹ãååç©5â²âã¢ã
ãã¡ãã«â4â²âã¡ãã«ããœã©ã¬ã³ããã³8â²âã¢ã
ãã¡ãã«ããœã©ã¬ã³ã¯ãïŒâã¡ãã«åºãæããªã
ããçŽ ææ§ã§ã¯æ¬è³ªçã«çµå£çã«ã¯äžæŽ»æ§ã§ã
ãããããæ¬çºæã®åéããã³é£æ¥åéã«ãã
ãŠãåŸæ¥ã§ã¯äºæ³ãããåŸãªãå æåæ§æŽ»æ§ã瀺
ããã®ã§ããã
æ¬çºæã®ç®çã¯ãæ°èŠãªããœã©ã¬ã³ååç©é¡ã
æäŸããããšã§ãããä»ã®ç®çã¯ããã®ä»ã®æ§é
ãæããããœã©ã¬ã³ååç©ãšæ¯ã¹ããšããé«ãç¹
æ§ã瀺ãæ°èŠãªããœã©ã¬ã³ååç©ãæäŸããããš
ã§ãããããã«å¥ã®ç®çã¯ãåè¿°ãããããªåºæº
ã«é¢ãé«ãå æåç¹æ§ãæããæ°èŠãªããœã©ã¬ã³
ååç©é¡ãæäŸããããšã§ããããŸãå¥ã®ç®çãš
ããŠã¯ãé«ãå æåç¹æ§ãšæ¯èŒçäœãæ¯æ§ãæã
ãã€åŸæ¥å ¬ç¥ã®ããœã©ã¬ã³ååç©é¡ãšã¯æ¬è³ªçã«
ç°ã€ãæ§é ãæããæ°èŠãªããœã©ã¬ã³ååç©é¡ã
æäŸããããšã§ããããã®åªããç¹è³ªã¯åŸæ¥å ¬ç¥
ã®æ§é äžæŽ»æ§çžé¢æ§ãæ ¹æ ãšããŠã¯äºèŠãåŸãªã
ã€ããã®ã§ãããããã«ä»ã®ç®çã¯åœè©²æè¡åé
ã®ãã®ã«ãšã€ãŠã¯æããã«èªããããã§ããã
ããããã«ä»ãå ããããç®çã以äžã®èšè¿°ãç¹
èš±è«æ±ã®ç¯å²ããæãããšãªãã§ãããã
æäŸããããšã§ãããä»ã®ç®çã¯ããã®ä»ã®æ§é
ãæããããœã©ã¬ã³ååç©ãšæ¯ã¹ããšããé«ãç¹
æ§ã瀺ãæ°èŠãªããœã©ã¬ã³ååç©ãæäŸããããš
ã§ãããããã«å¥ã®ç®çã¯ãåè¿°ãããããªåºæº
ã«é¢ãé«ãå æåç¹æ§ãæããæ°èŠãªããœã©ã¬ã³
ååç©é¡ãæäŸããããšã§ããããŸãå¥ã®ç®çãš
ããŠã¯ãé«ãå æåç¹æ§ãšæ¯èŒçäœãæ¯æ§ãæã
ãã€åŸæ¥å ¬ç¥ã®ããœã©ã¬ã³ååç©é¡ãšã¯æ¬è³ªçã«
ç°ã€ãæ§é ãæããæ°èŠãªããœã©ã¬ã³ååç©é¡ã
æäŸããããšã§ããããã®åªããç¹è³ªã¯åŸæ¥å ¬ç¥
ã®æ§é äžæŽ»æ§çžé¢æ§ãæ ¹æ ãšããŠã¯äºèŠãåŸãªã
ã€ããã®ã§ãããããã«ä»ã®ç®çã¯åœè©²æè¡åé
ã®ãã®ã«ãšã€ãŠã¯æããã«èªããããã§ããã
ããããã«ä»ãå ããããç®çã以äžã®èšè¿°ãç¹
èš±è«æ±ã®ç¯å²ããæãããšãªãã§ãããã
æ¬çºæã¯ã5â²âã¢ããã¢ã«ãã«â4â²ïŒïŒïŒïŒâ
ããªã¢ã«ãã«ããœã©ã¬ã³é¡ã«é¢ãããããã¯ä»ã®
ç°ã€ãæ§é ã®ããœã©ã¬ã³é¡ãšæ¯èŒãããšãé«ãå
æå掻æ§ãç¹å¥ã®çµå£ç掻æ§ãæããæ©æã®éå§
æã掻æ§ã®é«ããããæ倧å€ããã³å»¶é·ãããæ
ç¶æ§ãæããåæã«äœãæ¯æ§ãæãããã®ã§ã
ããæ§é ãç°ãã«ããããããããããååç©é¡
ã¯ãäžè¿°ããçš®ã ã®åºæºã«ãããŠæ¯èŒçäœãæ¯æ§
ãšãšãã«é¡èã«ããããå æå掻æ§ãæã€ããšã«
ãã€ãŠç¹åŸŽã¥ãããããæ¬çºæã¯ãç¹ã«5â²â第äž
çŽã¢ããäœçŽã¢ã«ãã«â4â²ïŒïŒïŒïŒâããªäœçŽã¢
ã«ãã«ããœã©ã¬ã³é¡ããã³ããšããã5â²âã¢ãã
ã¡ãã«âïŒïŒ4â²ïŒïŒâããªã¡ãã«ããœã©ã¬ã³ã«é¢
ãããã®ã§ããã
ããªã¢ã«ãã«ããœã©ã¬ã³é¡ã«é¢ãããããã¯ä»ã®
ç°ã€ãæ§é ã®ããœã©ã¬ã³é¡ãšæ¯èŒãããšãé«ãå
æå掻æ§ãç¹å¥ã®çµå£ç掻æ§ãæããæ©æã®éå§
æã掻æ§ã®é«ããããæ倧å€ããã³å»¶é·ãããæ
ç¶æ§ãæããåæã«äœãæ¯æ§ãæãããã®ã§ã
ããæ§é ãç°ãã«ããããããããããååç©é¡
ã¯ãäžè¿°ããçš®ã ã®åºæºã«ãããŠæ¯èŒçäœãæ¯æ§
ãšãšãã«é¡èã«ããããå æå掻æ§ãæã€ããšã«
ãã€ãŠç¹åŸŽã¥ãããããæ¬çºæã¯ãç¹ã«5â²â第äž
çŽã¢ããäœçŽã¢ã«ãã«â4â²ïŒïŒïŒïŒâããªäœçŽã¢
ã«ãã«ããœã©ã¬ã³é¡ããã³ããšããã5â²âã¢ãã
ã¡ãã«âïŒïŒ4â²ïŒïŒâããªã¡ãã«ããœã©ã¬ã³ã«é¢
ãããã®ã§ããã
æ¬çºæã®ååç©é¡ã¯ã以äžã®åŒãæãã5â²â第
äžçŽã¢ããäœçŽã¢ã«ãã«â4â²âäœçŽã¢ã«ãã«âïŒ
âäœçŽã¢ã«ãã«âïŒâäœçŽã¢ã«ãã«ããœã©ã¬ã³ã§
ãããç¹ã«ããã§äœçŽã¢ã«ãã«ãã¡ãã«åºã§ãã
ããšã奜ãŸãããã®ã§ããã
äžçŽã¢ããäœçŽã¢ã«ãã«â4â²âäœçŽã¢ã«ãã«âïŒ
âäœçŽã¢ã«ãã«âïŒâäœçŽã¢ã«ãã«ããœã©ã¬ã³ã§
ãããç¹ã«ããã§äœçŽã¢ã«ãã«ãã¡ãã«åºã§ãã
ããšã奜ãŸãããã®ã§ããã
以äžã®èª¿æŽæ³ããã³äŸã¯åã«äŸç€ºãšããŠç€ºãã
ããã®ã§ãããéå®ãšèŠåãããŠã¯ãªããªããã®
ã§ããã
ããã®ã§ãããéå®ãšèŠåãããŠã¯ãªããªããã®
ã§ããã
é©åœãªåºçºç©è³ªã§ãããŠã³ããªããšãã³ïŒïŒâ
ã¢ã«ãã«ããã³ïŒïŒïŒâãžã¢ã«ãã«âïŒâããã
ãã·ã¯ããªã³é¡ïŒã¯ãå ¬ç¥æ¹æ³ã§èª¿è£œããåŸãå ¬
ç¥ååç©ã§ãããå ¬ç¥ã®æ¹æ³ããã¯ã¬ãªãŒããã
ã³ã¯ãŒã¹èãããã©ãããã³ã»ã¬ã¿ãŒïŒMacL
eod and WorthïŒTetrahedron Lett.ïŒïŒ237â240
ïŒ1972ïŒãã«ãã€ãŠçš®ã ã®ã¢ã«ãã«çœ®æã®ããœã©ã¬
ã³é¡ã«å€æãåŸãååç©ã§ãããåºçºã®ïŒïŒãã
ã³ïŒïŒâã¢ã«ãã«çœ®æäœãšã¢ã«ãã«ããã¡ãã«ã±
ãã³åå¿å€ã«ãããŠéžæçã«å€åãããããšãå ¬
ç¥ã®ïŒïŒ4â²ïŒïŒâããªã¡ãã«ããœã©ã¬ã³ããã
ã«ïŒãŸãã¯ïŒïŒ4â²ãïŒã®äœçœ®ã§ã®ãã¢ã«ãã«åºã
å€åãããããœã©ã¬ã³ãåŸãããããã®ããšã¯ã
ãååã«ä»¥äžã«ç€ºããããã®ã§ãããç¹ã«äŸç€ºãš
ããŠä»¥äžã«ç€ºããããéžæãããαâã¯ããã¢ã«
ãã«ã¡ãã«ãšãŒãã«ã§ã®ã¯ããã¢ã«ãã«åã¯ã
4â²ïŒïŒïŒïŒâããªã¢ã«ãã«ããœã©ã¬ã³æ žã®5â²ã®äœ
眮ã«ç®çãšããäºãéžæãããã¯ããã¢ã«ãã«åº
ãå°å ¥ãåŸããã®åŸãã¿ãªããã«ãªãŠã ãšåå¿
ããã€ãã§ããã©ãžã³ããã©ãŒãã«ããéè£åå¿
ïŒãããžããªã·ã¹ïŒã«ããç®çãšãã5â²âã¢ãã
ã¢ã«ãã«â4â²ïŒïŒïŒïŒâããªã¢ã«ãã«ããœã©ã¬ã³
ãåŸããããããã§çš®ã ã®ã¢ã«ãã«åºã¯çšããã
ãåºçºç©è³ªã®ïŒïŒïŒâãžã¢ã«ãã«âïŒâãããã
ã·ã¯ããªã³ãã¢ã«ãã«ããã¡ãã«ã±ãã³ããã³ã¯
ããã¢ã«ãã«åå€ã«ãããããããã«å¯Ÿå¿ããã
å¥æ³ãšããŠãããã¢ã«ãã«åã¯ããªã©ãŒããã³ã¯
ãŒã³èãžã€ãŒãã«ããªãããªãŒã¬ããã¯ãã±ãã¹
ããªãŒïŒOlah and KuhnïŒJ.Org.Chem.ïŒç¬¬29
å·»ã2317é ïŒ1964ïŒãŸãã¯ããªãŒãã«âã¯ã©ã
ããã¢ã³ãããªã¬ã€ãããããªã¢ã¯ã·ãšã³ãº
ïŒFriedelâGrafts and Related ReactionsïŒç¬¬
å·» 第ïŒéšããžãŒïŒãšãŒïŒãªã©ãŒïŒG.A.OlahïŒ
ç·šïŒInterscienceåãããŠãŒãšãŒã¯ã1964ã749
é ïŒã«ãã€ãŠæããã«ãããŠãããæåŸã®5â²âã¢
ããã¢ã«ãã«â4â²ïŒïŒïŒïŒâããªã¢ã«ãã«ããœã©
ã¬ã³ã®æ§é ã¯ãããŒãã³ãšã«ããŒã¢ãã«
ïŒPerkin Elmer ModelïŒïŒ²â24BãçšããŠæ žç£æ°
å ±é³Žã¹ãã¯ãã«ããã³å çŽ åæã«ãã€ãŠæ±ºå®ãã
ããèç¹ã¯è£æ£ãããŠããªãã
ã¢ã«ãã«ããã³ïŒïŒïŒâãžã¢ã«ãã«âïŒâããã
ãã·ã¯ããªã³é¡ïŒã¯ãå ¬ç¥æ¹æ³ã§èª¿è£œããåŸãå ¬
ç¥ååç©ã§ãããå ¬ç¥ã®æ¹æ³ããã¯ã¬ãªãŒããã
ã³ã¯ãŒã¹èãããã©ãããã³ã»ã¬ã¿ãŒïŒMacL
eod and WorthïŒTetrahedron Lett.ïŒïŒ237â240
ïŒ1972ïŒãã«ãã€ãŠçš®ã ã®ã¢ã«ãã«çœ®æã®ããœã©ã¬
ã³é¡ã«å€æãåŸãååç©ã§ãããåºçºã®ïŒïŒãã
ã³ïŒïŒâã¢ã«ãã«çœ®æäœãšã¢ã«ãã«ããã¡ãã«ã±
ãã³åå¿å€ã«ãããŠéžæçã«å€åãããããšãå ¬
ç¥ã®ïŒïŒ4â²ïŒïŒâããªã¡ãã«ããœã©ã¬ã³ããã
ã«ïŒãŸãã¯ïŒïŒ4â²ãïŒã®äœçœ®ã§ã®ãã¢ã«ãã«åºã
å€åãããããœã©ã¬ã³ãåŸãããããã®ããšã¯ã
ãååã«ä»¥äžã«ç€ºããããã®ã§ãããç¹ã«äŸç€ºãš
ããŠä»¥äžã«ç€ºããããéžæãããαâã¯ããã¢ã«
ãã«ã¡ãã«ãšãŒãã«ã§ã®ã¯ããã¢ã«ãã«åã¯ã
4â²ïŒïŒïŒïŒâããªã¢ã«ãã«ããœã©ã¬ã³æ žã®5â²ã®äœ
眮ã«ç®çãšããäºãéžæãããã¯ããã¢ã«ãã«åº
ãå°å ¥ãåŸããã®åŸãã¿ãªããã«ãªãŠã ãšåå¿
ããã€ãã§ããã©ãžã³ããã©ãŒãã«ããéè£åå¿
ïŒãããžããªã·ã¹ïŒã«ããç®çãšãã5â²âã¢ãã
ã¢ã«ãã«â4â²ïŒïŒïŒïŒâããªã¢ã«ãã«ããœã©ã¬ã³
ãåŸããããããã§çš®ã ã®ã¢ã«ãã«åºã¯çšããã
ãåºçºç©è³ªã®ïŒïŒïŒâãžã¢ã«ãã«âïŒâãããã
ã·ã¯ããªã³ãã¢ã«ãã«ããã¡ãã«ã±ãã³ããã³ã¯
ããã¢ã«ãã«åå€ã«ãããããããã«å¯Ÿå¿ããã
å¥æ³ãšããŠãããã¢ã«ãã«åã¯ããªã©ãŒããã³ã¯
ãŒã³èãžã€ãŒãã«ããªãããªãŒã¬ããã¯ãã±ãã¹
ããªãŒïŒOlah and KuhnïŒJ.Org.Chem.ïŒç¬¬29
å·»ã2317é ïŒ1964ïŒãŸãã¯ããªãŒãã«âã¯ã©ã
ããã¢ã³ãããªã¬ã€ãããããªã¢ã¯ã·ãšã³ãº
ïŒFriedelâGrafts and Related ReactionsïŒç¬¬
å·» 第ïŒéšããžãŒïŒãšãŒïŒãªã©ãŒïŒG.A.OlahïŒ
ç·šïŒInterscienceåãããŠãŒãšãŒã¯ã1964ã749
é ïŒã«ãã€ãŠæããã«ãããŠãããæåŸã®5â²âã¢
ããã¢ã«ãã«â4â²ïŒïŒïŒïŒâããªã¢ã«ãã«ããœã©
ã¬ã³ã®æ§é ã¯ãããŒãã³ãšã«ããŒã¢ãã«
ïŒPerkin Elmer ModelïŒïŒ²â24BãçšããŠæ žç£æ°
å ±é³Žã¹ãã¯ãã«ããã³å çŽ åæã«ãã€ãŠæ±ºå®ãã
ããèç¹ã¯è£æ£ãããŠããªãã
5â²âã¢ããã¡ãã«â4â²ïŒïŒïŒïŒâããªã¡ãã«ããœ
ã©ã¬ã³ 5â²âã¯ããã¡ãã«âïŒïŒ4â²ïŒïŒâããªã¡ãã«ã
ãœã©ã¬ã³ãæ°·é ¢é žïŒ1.3ïŒäžã®ïŒïŒ4â²ïŒïŒâã
ãªã¡ãã«ããœã©ã¬ã³ïŒïŒïŒ4â²ïŒïŒâTMPïŒïŒ29.36
ïœïŒ0.13ã¢ã«ïŒæº¶æ¶²ã«ã宀枩äžã«ã¯ããã¡ãã«ã¡
ãã«ãšãŒãã«ïŒ200mlïŒãæ·»å ãããã48æéåŸ
çœãæ²æŸ±ç©ã圢æããå¥ããããçµæ¶ã¯é¢šä¹Ÿã
ã28.63ïœïŒ80ïŒ ïŒã®5â²âã¯ããã¡ãã«âïŒïŒ4â²ïŒ
ïŒâããªã¡ãã«ããœã©ã¬ã³ãåŸããããèç¹169
ã171âïŒNMRïŒCDCïŒïŒÎŽ2.29ïŒïœïŒ3HïŒïŒ
2.46ïŒïœïŒ3HïŒïŒ2.54ïŒïœïŒ3HïŒïŒ4.67ïŒïœïŒ
2HïŒïŒ6.14ïŒïœïŒ1HïŒïŒ7.3ïŒïœïŒ1HïŒã
ã©ã¬ã³ 5â²âã¯ããã¡ãã«âïŒïŒ4â²ïŒïŒâããªã¡ãã«ã
ãœã©ã¬ã³ãæ°·é ¢é žïŒ1.3ïŒäžã®ïŒïŒ4â²ïŒïŒâã
ãªã¡ãã«ããœã©ã¬ã³ïŒïŒïŒ4â²ïŒïŒâTMPïŒïŒ29.36
ïœïŒ0.13ã¢ã«ïŒæº¶æ¶²ã«ã宀枩äžã«ã¯ããã¡ãã«ã¡
ãã«ãšãŒãã«ïŒ200mlïŒãæ·»å ãããã48æéåŸ
çœãæ²æŸ±ç©ã圢æããå¥ããããçµæ¶ã¯é¢šä¹Ÿã
ã28.63ïœïŒ80ïŒ ïŒã®5â²âã¯ããã¡ãã«âïŒïŒ4â²ïŒ
ïŒâããªã¡ãã«ããœã©ã¬ã³ãåŸããããèç¹169
ã171âïŒNMRïŒCDCïŒïŒÎŽ2.29ïŒïœïŒ3HïŒïŒ
2.46ïŒïœïŒ3HïŒïŒ2.54ïŒïœïŒ3HïŒïŒ4.67ïŒïœïŒ
2HïŒïŒ6.14ïŒïœïŒ1HïŒïŒ7.3ïŒïœïŒ1HïŒã
5â²ââãã¿ãªããã¡ãã«âïŒïŒ4â²ïŒïŒâããª
ã¡ãã«ããœã©ã¬ã³ã5â²âã¯ããã¡ãã«âïŒïŒ4â²ïŒ
ïŒâããªã¡ãã«ããœã©ã¬ã³ïŒ13.63ïœã0.05ã¢
ã«ïŒããã³ãã¿ãªããã«ãªãŠã ïŒ11.1ïœã0.06ã¢
ã«ïŒã®ãžã¡ãã«ãã«ã ã¢ããïŒ1.4ïŒæº¶æ¶²ã100
âã«ãŠïŒæéæ¹æãããå·åŽããã³æ°ŽïŒ3.0ïŒ
ã§ã®åžéã®åŸãæ²æŸ±ç©ãéããã也ç¥ããã
17.95ïœïŒ92.7ïŒ ïŒã®5â²ââãã¿ãªããã¡ãã«â
ïŒïŒ4â²ïŒïŒâããªã¡ãã«ããœã©ã¬ã³ãåŸãããã
ã¡ãã«ããœã©ã¬ã³ã5â²âã¯ããã¡ãã«âïŒïŒ4â²ïŒ
ïŒâããªã¡ãã«ããœã©ã¬ã³ïŒ13.63ïœã0.05ã¢
ã«ïŒããã³ãã¿ãªããã«ãªãŠã ïŒ11.1ïœã0.06ã¢
ã«ïŒã®ãžã¡ãã«ãã«ã ã¢ããïŒ1.4ïŒæº¶æ¶²ã100
âã«ãŠïŒæéæ¹æãããå·åŽããã³æ°ŽïŒ3.0ïŒ
ã§ã®åžéã®åŸãæ²æŸ±ç©ãéããã也ç¥ããã
17.95ïœïŒ92.7ïŒ ïŒã®5â²ââãã¿ãªããã¡ãã«â
ïŒïŒ4â²ïŒïŒâããªã¡ãã«ããœã©ã¬ã³ãåŸãããã
5â²âã¢ããã¡ãã«âïŒïŒ4â²ïŒïŒâããªã¡ãã«ã
ãœã©ã¬ã³ïŒ5â²ââãã¿ãªããã¡ãã«âïŒïŒ4â²ïŒ
ïŒâããªã¡ãã«ããœã©ã¬ã³ïŒ17.95ïœã0.046ã¢
ã«ïŒãããã©ãžã³ããã©ãŒãïŒ21.1mlïŒã®ããã³
95ïŒ ãšã¿ããŒã«ïŒïŒïŒã®æ··åç©ãéæµäžïŒæé
å ç±ãããããŒã¿ãªãŒèžçºåšäžã§æ¿çž®ãããæ®éš
ã¯0.1Nã®NaOHïŒ4.0ïŒã«æº¶è§£ããããCHC
ïŒã®äžã€ã®éšåïŒ300mlïŒã5.8ïœïŒ49ïŒ ïŒã®é»è²
åºäœãèç¹193ã201âãæœåºããããã®åºäœã¯
179âã§36æéæè¯ãããããã2.5ïœã®ç©è³ªãåŸ
ããããã¯ãã³ãŒã³ïŒãªã°ãã€ã³ããã®åçµæ¶ã®
ã®ã¡ãããçŽç²ãªç©è³ª1.9ïœãšãªã€ããèç¹197ã
199âïŒNMRïŒCDCïŒïŒÎŽ1.7ïŒãããŒãïœïŒ
2HïŒïŒ2.21ïŒïœïŒ3HïŒïŒ2.44ïŒïœïŒ3HïŒïŒ2.48
ïŒïœïŒ3HïŒïŒ3.93ïŒïœïŒ2HïŒïŒ6.15ïŒïœïŒ1HïŒïŒ
7.35ïŒïœïŒ1HïŒããã®ç©ã¯å çŽ åæã«äŸããã
5â²âã¢ããã¡ãã«âïŒïŒ4â²ïŒïŒâããªã¡ãã«ããœ
ã©ã¬ã³ã§ããããšãå€æããã
ãœã©ã¬ã³ïŒ5â²ââãã¿ãªããã¡ãã«âïŒïŒ4â²ïŒ
ïŒâããªã¡ãã«ããœã©ã¬ã³ïŒ17.95ïœã0.046ã¢
ã«ïŒãããã©ãžã³ããã©ãŒãïŒ21.1mlïŒã®ããã³
95ïŒ ãšã¿ããŒã«ïŒïŒïŒã®æ··åç©ãéæµäžïŒæé
å ç±ãããããŒã¿ãªãŒèžçºåšäžã§æ¿çž®ãããæ®éš
ã¯0.1Nã®NaOHïŒ4.0ïŒã«æº¶è§£ããããCHC
ïŒã®äžã€ã®éšåïŒ300mlïŒã5.8ïœïŒ49ïŒ ïŒã®é»è²
åºäœãèç¹193ã201âãæœåºããããã®åºäœã¯
179âã§36æéæè¯ãããããã2.5ïœã®ç©è³ªãåŸ
ããããã¯ãã³ãŒã³ïŒãªã°ãã€ã³ããã®åçµæ¶ã®
ã®ã¡ãããçŽç²ãªç©è³ª1.9ïœãšãªã€ããèç¹197ã
199âïŒNMRïŒCDCïŒïŒÎŽ1.7ïŒãããŒãïœïŒ
2HïŒïŒ2.21ïŒïœïŒ3HïŒïŒ2.44ïŒïœïŒ3HïŒïŒ2.48
ïŒïœïŒ3HïŒïŒ3.93ïŒïœïŒ2HïŒïŒ6.15ïŒïœïŒ1HïŒïŒ
7.35ïŒïœïŒ1HïŒããã®ç©ã¯å çŽ åæã«äŸããã
5â²âã¢ããã¡ãã«âïŒïŒ4â²ïŒïŒâããªã¡ãã«ããœ
ã©ã¬ã³ã§ããããšãå€æããã
åæïŒçè«å€ C15H15NO3ãšããŠïŒïŒ£ïŒ70.02ïŒ
ïŒ5.88ïŒïŒ®ïŒ5.44. åæå€ ïŒ£ïŒ69.74ïŒïŒšïŒ6.14ïŒïŒ®ïŒ5.68. 5â²âã¢ãããšãã«â4â²âãšãã«âïŒïŒïŒâãžã¡ã
ã«ããœã©ã¬ã³ïŒ äžè¿°ã§ç€ºããããšåæ§ã«ããŠããã ã第ïŒã®æ
äœã«ãããŠ4â²âãšãã«âïŒïŒïŒâãžã¡ãã«ããœã©
ã¬ã³ããã³Î±âã¯ããã¡ãã«ã¡ãã«ãšãŒãã«ãçš
ããããšã§è¡šèšã®ååç©ã調æŽããã
ïŒ5.88ïŒïŒ®ïŒ5.44. åæå€ ïŒ£ïŒ69.74ïŒïŒšïŒ6.14ïŒïŒ®ïŒ5.68. 5â²âã¢ãããšãã«â4â²âãšãã«âïŒïŒïŒâãžã¡ã
ã«ããœã©ã¬ã³ïŒ äžè¿°ã§ç€ºããããšåæ§ã«ããŠããã ã第ïŒã®æ
äœã«ãããŠ4â²âãšãã«âïŒïŒïŒâãžã¡ãã«ããœã©
ã¬ã³ããã³Î±âã¯ããã¡ãã«ã¡ãã«ãšãŒãã«ãçš
ããããšã§è¡šèšã®ååç©ã調æŽããã
5â²âã¢ããã¡ãã«â4â²8âãžã¡ãã«âïŒâããã
ã«ããœã©ã¬ã³ äžè¿°ã§ç€ºããããšåæ§ã«ããŠããã ã第ïŒã®æ
äœã«ãããŠã4â²ïŒïŒâãžã¡ãã«âïŒâãããã«ã
ãœã©ã¬ã³ãçšããããšã§è¡šèšã®ååç©ã調æŽã
ãã
ã«ããœã©ã¬ã³ äžè¿°ã§ç€ºããããšåæ§ã«ããŠããã ã第ïŒã®æ
äœã«ãããŠã4â²ïŒïŒâãžã¡ãã«âïŒâãããã«ã
ãœã©ã¬ã³ãçšããããšã§è¡šèšã®ååç©ã調æŽã
ãã
5â²âã¢ããã¡ãã«âïŒïŒ4â²âãžã¡ãã«âïŒâãšã
ã«ããœã©ã¬ã³ïŒ äžè¿°ã§ç€ºããããšåæ§ã«ããŠããã ã第ïŒã®æ
äœã«ãããŠ4â²ïŒïŒâãžã¡ãã«âïŒâãšãã«ããœã©
ã¬ã³ããåºçºããŠè¡šèšã®ååç©ã調æŽããã
ã«ããœã©ã¬ã³ïŒ äžè¿°ã§ç€ºããããšåæ§ã«ããŠããã ã第ïŒã®æ
äœã«ãããŠ4â²ïŒïŒâãžã¡ãã«âïŒâãšãã«ããœã©
ã¬ã³ããåºçºããŠè¡šèšã®ååç©ã調æŽããã
äžè¿°ã§ç€ºããããšåæ§ã«ããŠãåºçºç©è³ªãéžã¶
ããšã«ããä»ã®å€åãæªçºæã®ç¯å²å ã«ããä»ã®
5â²âã¢ããäœçŽã¢ã«ãã«â4â²ïŒïŒïŒïŒâããªäœçŽ
ã¢ã«ãã«ããœã©ã¬ã³é¡ã®èª¿æŽã«ç€ºããããããã§
ã¯ååäžã«ååšããïŒåãïŒåãªããå šãŠã®äœçŽ
ã¢ã«ãã«åºãå€ããããããã§ã«çšããããŠãã
ããã«ããäœçŽã¢ã«ãã«ããªãçšèªã¯ãïŒãïŒã®
ççŽ ååãæããçŽéãŸãã¯åå²éã®å®®èœåºãªã
ãã©ãžã«ã«ãæå³ãã奜ãŸããã¯ïŒãïŒã®ççŽ æ°
ã®ãã®ã§ãããã¡ãã«ããšãã«ããããã«ãã€ãœ
ãããã«ãããã«çã®ãããªãã®ãå«ãŸããã
ããšã«ããä»ã®å€åãæªçºæã®ç¯å²å ã«ããä»ã®
5â²âã¢ããäœçŽã¢ã«ãã«â4â²ïŒïŒïŒïŒâããªäœçŽ
ã¢ã«ãã«ããœã©ã¬ã³é¡ã®èª¿æŽã«ç€ºããããããã§
ã¯ååäžã«ååšããïŒåãïŒåãªããå šãŠã®äœçŽ
ã¢ã«ãã«åºãå€ããããããã§ã«çšããããŠãã
ããã«ããäœçŽã¢ã«ãã«ããªãçšèªã¯ãïŒãïŒã®
ççŽ ååãæããçŽéãŸãã¯åå²éã®å®®èœåºãªã
ãã©ãžã«ã«ãæå³ãã奜ãŸããã¯ïŒãïŒã®ççŽ æ°
ã®ãã®ã§ãããã¡ãã«ããšãã«ããããã«ãã€ãœ
ãããã«ãããã«çã®ãããªãã®ãå«ãŸããã
5â²âã¢ããã¡ãã«âN4â²âã¡ãã«ããœã©ã¬ã³ã¯
ïŒâããããã·ã¯ããªã³ããåºçºããŠãæ¯èŒã®ã
ãã«åæ§ã«ããŠèª¿æŽãããããã®èª¿æŽã®æçµæäœ
ã¯ä»¥äžã®ãšããã§ããïŒ 4â²âã¡ãã«â5â²âãã¿ãªããã¡ãã«ããœã©ã¬ã³
ïŒ6.0ïœïŒ16.7ããªã¢ã«ïŒãç¡æ°Žãšã¿ããŒã«ïŒ1.2
ïŒãæ°·é ¢é žïŒ15.24mlã266ããªã¢ã«ïŒããã³85
ïŒ ããã©ãžã³ããã©ãŒãïŒ7.63mlã133ããªã¢
ã«ïŒã®æ··åç©ãéæµäžïŒæéå ç±ãããã€ãã§ç
空äžæ¿çž®ãããç°è²ããã€ãçœè²ã®åºäœãåŸãã
HClïŒ1FïŒ500mlïŒãå ããã€ãã§PHãçŽ8.0ã«ãª
ããŸã§NaHCO3ïŒåºäœïŒãå ããæ··åç©ã¯ä¹Ÿç¥
ïŒNa2SO4ïŒãããCHCl3ã®äžã€ã®éšåïŒ500mlïŒæœ
åºãããã€ãã§ç空äžæ¿çž®ããã5â²âã¢ããã¡ã
ã«â4â²ã¡ãã«ã«ããœã©ã¬ã³ïŒ2.94ïœã77ïŒ ïŒãè
ç¹153.1ã156.3âãåŸãããã³ãŒã³âãªã°ãã€ã³
ïŒæ²žç¹94ã105âïŒæº¶åªå¯Ÿããã®åçµæ¶ã§ãåæå€
ïŒ73ïŒ ååçïŒã¯ãèç¹154.1ã156.1âãNMR
ïŒCDCl3ïŒÎŽ1.7ïŒãããŒãïœïŒïŒïŒNH2ïŒD2Oã§äº€
æå¯èœïŒã2.25ïŒïœïŒïŒïŒ4â²âCH3ïŒ3.95ïŒïœïŒ
ïŒïŒCH2ïŒïŒ6.31ïŒïœïŒïŒïŒïŒªïŒïŒHzïŒC3HïŒïŒ
7.32ïŒïœïŒïŒïŒC8HïŒïŒ7.46ïŒïœïŒïŒïŒC5HïŒïŒ
7.75ïŒïœïŒïŒïŒïŒªïŒïŒHzïŒC4HïŒã§ãã€ãã
ïŒâããããã·ã¯ããªã³ããåºçºããŠãæ¯èŒã®ã
ãã«åæ§ã«ããŠèª¿æŽãããããã®èª¿æŽã®æçµæäœ
ã¯ä»¥äžã®ãšããã§ããïŒ 4â²âã¡ãã«â5â²âãã¿ãªããã¡ãã«ããœã©ã¬ã³
ïŒ6.0ïœïŒ16.7ããªã¢ã«ïŒãç¡æ°Žãšã¿ããŒã«ïŒ1.2
ïŒãæ°·é ¢é žïŒ15.24mlã266ããªã¢ã«ïŒããã³85
ïŒ ããã©ãžã³ããã©ãŒãïŒ7.63mlã133ããªã¢
ã«ïŒã®æ··åç©ãéæµäžïŒæéå ç±ãããã€ãã§ç
空äžæ¿çž®ãããç°è²ããã€ãçœè²ã®åºäœãåŸãã
HClïŒ1FïŒ500mlïŒãå ããã€ãã§PHãçŽ8.0ã«ãª
ããŸã§NaHCO3ïŒåºäœïŒãå ããæ··åç©ã¯ä¹Ÿç¥
ïŒNa2SO4ïŒãããCHCl3ã®äžã€ã®éšåïŒ500mlïŒæœ
åºãããã€ãã§ç空äžæ¿çž®ããã5â²âã¢ããã¡ã
ã«â4â²ã¡ãã«ã«ããœã©ã¬ã³ïŒ2.94ïœã77ïŒ ïŒãè
ç¹153.1ã156.3âãåŸãããã³ãŒã³âãªã°ãã€ã³
ïŒæ²žç¹94ã105âïŒæº¶åªå¯Ÿããã®åçµæ¶ã§ãåæå€
ïŒ73ïŒ ååçïŒã¯ãèç¹154.1ã156.1âãNMR
ïŒCDCl3ïŒÎŽ1.7ïŒãããŒãïœïŒïŒïŒNH2ïŒD2Oã§äº€
æå¯èœïŒã2.25ïŒïœïŒïŒïŒ4â²âCH3ïŒ3.95ïŒïœïŒ
ïŒïŒCH2ïŒïŒ6.31ïŒïœïŒïŒïŒïŒªïŒïŒHzïŒC3HïŒïŒ
7.32ïŒïœïŒïŒïŒC8HïŒïŒ7.46ïŒïœïŒïŒïŒC5HïŒïŒ
7.75ïŒïœïŒïŒïŒïŒªïŒïŒHzïŒC4HïŒã§ãã€ãã
åæïŒçè«å€ C13H11O3NãšããŠïŒïŒ£ïŒ68.11ïŒ
ïŒ4.84ïŒïŒ®ïŒ6.11 枬å®å€ ïŒ67.94ïŒH4.85ïŒïŒ®ïŒ5.82ã
ïŒ4.84ïŒïŒ®ïŒ6.11 枬å®å€ ïŒ67.94ïŒH4.85ïŒïŒ®ïŒ5.82ã
è¬ å¹
æ¬çºæã«ããååç©ã®çäœå
å
æåæ§ã¯ãã倩
ç¶ãªãã³ã«åæããã¯ããªã³é¡ã®çç©åŠçæ€å®
æ³ããªãè¡šé¡ã§J.Invest.Dermatol.32ïŒ509ã518
ïŒ1959ïŒã«çºè¡šããããã¿ã¯ããã³ãã€ãããã
ãªãã¯ïŒPathak and FitzpatrickïŒã®å€æ³ã«ã
ããã€ãŠçŽ æåå¿ã®èçŒçè©ç¹æ³ã«ããå®éãã
ãïŒããœã©ã¬ã³æ°ã¯ããã¡ããããã¯ããªã³æã®
ç·ç¶ç°æ§äœã§ãããïŒå æåæ§æŽ»æ§ã®æ¬çç©åŠç
æ€å®æ³ã«ããã°ãçœè²ã¢ã«ã¢ããïŒalbino
quinea pigïŒã®ç®èäžã®çŽ æçæã¯èçŒã§æž¬å®ã
ãããã®åå¿ã¯ïŒ¯ïŒåïŒïŒïŒïŒïŒïŒããã³ïŒã®æ®µ
éã«å¿ããŠççŽåãããã䜿çšããå€æ³ã¯ãè©Šéš
ååç©æäžãã玫å€ç·ç §å°ãŸã§ã®æéå€åãå«
ã¿ããããã€ãŠèªçºãããå æåæ§å¹æã®éå§ãª
ãã³ã«äœäžæéã®æž¬å®ãå¯èœã§ããã
ç¶ãªãã³ã«åæããã¯ããªã³é¡ã®çç©åŠçæ€å®
æ³ããªãè¡šé¡ã§J.Invest.Dermatol.32ïŒ509ã518
ïŒ1959ïŒã«çºè¡šããããã¿ã¯ããã³ãã€ãããã
ãªãã¯ïŒPathak and FitzpatrickïŒã®å€æ³ã«ã
ããã€ãŠçŽ æåå¿ã®èçŒçè©ç¹æ³ã«ããå®éãã
ãïŒããœã©ã¬ã³æ°ã¯ããã¡ããããã¯ããªã³æã®
ç·ç¶ç°æ§äœã§ãããïŒå æåæ§æŽ»æ§ã®æ¬çç©åŠç
æ€å®æ³ã«ããã°ãçœè²ã¢ã«ã¢ããïŒalbino
quinea pigïŒã®ç®èäžã®çŽ æçæã¯èçŒã§æž¬å®ã
ãããã®åå¿ã¯ïŒ¯ïŒåïŒïŒïŒïŒïŒïŒããã³ïŒã®æ®µ
éã«å¿ããŠççŽåãããã䜿çšããå€æ³ã¯ãè©Šéš
ååç©æäžãã玫å€ç·ç §å°ãŸã§ã®æéå€åãå«
ã¿ããããã€ãŠèªçºãããå æåæ§å¹æã®éå§ãª
ãã³ã«äœäžæéã®æž¬å®ãå¯èœã§ããã
ãããã³ã«
å±ææäžïŒ
åè¬ç©ã¯ãå±æã§ãšã¿ããŒã«æº¶æ¶²äžã®æ¿åºŠïŒïŒ
ã§è©Šéšããããç®èäžã®åïŒcm2ã®è©Šéšéšäœã«ã玫
å€ç·ããïŒãžãŠãŒã«ç §å°30ååã«éžæããç¹å®
ã®è©Šéšå溶液0.1mlãå¡åžããããåè©Šéšã«å¿
ããå矀ã®ã¢ã«ã¢ãã15å¹ã§ïŒçš®é¡ããæäžåŸ24
ããã³48æé芳å¯ãšççŽã¥ãã«ãã€ãŠå®ãããã
ãåå¿åŒ·åºŠããšåä»ããå¹³ååå¿ã«å°éãããã
ã«è©Šéšãããã
ã§è©Šéšããããç®èäžã®åïŒcm2ã®è©Šéšéšäœã«ã玫
å€ç·ããïŒãžãŠãŒã«ç §å°30ååã«éžæããç¹å®
ã®è©Šéšå溶液0.1mlãå¡åžããããåè©Šéšã«å¿
ããå矀ã®ã¢ã«ã¢ãã15å¹ã§ïŒçš®é¡ããæäžåŸ24
ããã³48æé芳å¯ãšççŽã¥ãã«ãã€ãŠå®ãããã
ãåå¿åŒ·åºŠããšåä»ããå¹³ååå¿ã«å°éãããã
ã«è©Šéšãããã
çµå£æäžïŒ
åè¬ç©ã¯ïŒçŸ€15å¹ã®ã¢ã«ã¢ããã«40mgïŒKgçµå£
æäžãããããšã«ãã€ãŠè©Šéšããããååç©ãžã®
é©åœãªæäžéããŒã©ãã³ã«ãã»ã«ã«å å¡«ãããå
ç©ã®åœé ã®å¥¥ã«æäžããããæ°ŽïŒmlãã泚å°çã§
é蟌ãŸããå¥äžãå©ãããåç©ã¯ãåè©Šéšåæäž
ååŸïŒæéã¯é£²é£ãããªãã玫å€ç·ãããç §å°
ã®ç·éã¯ãæäžåŸã10ïŒ20ïŒ30ïŒ45ïŒ60ïŒ90ïŒ
120ïŒ180ïŒ240åã«ïŒcm2åœãïŒãžãŠãŒã«ã§ããã
çµæã®è§£éãšè©äŸ¡ã¯ãæäžåŸ48æéã«è¡ãªããç¹
å®ã®è©Šéšåãããã®è©Šéšã§ãäŸå€çã«æŽ»æ§ãé«ã
å Žåã¯ãçµå£æäžéã¯ãã¡ããååã«ããããã
ãã¯æžããã
æäžãããããšã«ãã€ãŠè©Šéšããããååç©ãžã®
é©åœãªæäžéããŒã©ãã³ã«ãã»ã«ã«å å¡«ãããå
ç©ã®åœé ã®å¥¥ã«æäžããããæ°ŽïŒmlãã泚å°çã§
é蟌ãŸããå¥äžãå©ãããåç©ã¯ãåè©Šéšåæäž
ååŸïŒæéã¯é£²é£ãããªãã玫å€ç·ãããç §å°
ã®ç·éã¯ãæäžåŸã10ïŒ20ïŒ30ïŒ45ïŒ60ïŒ90ïŒ
120ïŒ180ïŒ240åã«ïŒcm2åœãïŒãžãŠãŒã«ã§ããã
çµæã®è§£éãšè©äŸ¡ã¯ãæäžåŸ48æéã«è¡ãªããç¹
å®ã®è©Šéšåãããã®è©Šéšã§ãäŸå€çã«æŽ»æ§ãé«ã
å Žåã¯ãçµå£æäžéã¯ãã¡ããååã«ããããã
ãã¯æžããã
ççŽã¥ãïŒ
åå¿ã¯ã以äžã®ããã«ççŽã¥ãããã
ïŒ åå¿ãªãã± ããããªçŽ
æãïŒïŒ çŽ
æã
ïŒïŒ çŽ æããã³å ããªæµ®è «ãïŒïŒ çŽ æããã³
匷ãæµ®è « ïŒïŒ 氎泡åå¿ã
ïŒïŒ çŽ æããã³å ããªæµ®è «ãïŒïŒ çŽ æããã³
匷ãæµ®è « ïŒïŒ 氎泡åå¿ã
çµ æ
æ¬çºæã«ããååç©ã¯ãå±ææäžåŸã24ããã³
48æéã®æž¬å®ã§çŽ æ圢æ掻æ§ã瀺ãããããã¯çµ
å£æäžåŸ48æéã®æž¬å®ã§é¡èãªæŽ»æ§ã瀺ããå æ
åæ§ã®å¹åã®é«ã極倧ãéãããªäœçšçºçŸãªãã³
ã«æ¥éãªäœçšäœäžã䌎ãªããååç©5â²âã¢ããã¡
ãã«â4â²ïŒïŒïŒïŒâããªã¡ãã«ããœã©ã¬ã³ã¯ç¹ã«
é¡èã§ããã240ãè¶ããã€360åãŸã§æ°Žæ³¡åå¿ã
éããã«äœçšçºçŸãã30ã360åéæ倧å€ãä¿
ã¡ãå ã10åã§åŒ·ãçŽ æã®åæéå§æãæããŠã
ãã20mgïŒKgã§ã¯å ãã«æŽ»æ§ãå£ãã ãã§ã10
mgïŒKgã«ãããŠãããè¿ éãªåŒ·ãé·æéã®æŽ»æ§ã®
æå¹æ§ãæãããïŒâã¢ããã¡ãã«âïŒïŒ5â²âïŒ
âããªã¡ãã«ããœã©ã¬ã³ãšæ¯ã¹ããšãå æåæ§ã®
æ倧å€ãæ倧å€ãžã®éå§æããã³æ倧å€ã®ç¶ææ
éã®ç¹ã§ã¯ããã«åªããŠãããã®ã§ããããã®å
æåå¹æã¯ããŸã10mgïŒKgã®ïŒåã®ïŒã®çµå£æäž
ã§ãå šãŠã®é¢ã§åªãããã®ã§ãããããã«å¯Ÿã
ãŠã5â²âã¢ããã¡ãã«â4â²âã¡ãã«ããœã©ã¬ã³
ïŒïŒâããããã·ã¯ããªã³ãšåäžæ¹æ³ã§è£œé ïŒ
ã¯ã24æéããã³48æéã§ïŒïŒïŒïŒïŒã®å±æåå¿
ã瀺ããšã¯ãããçµå£ã§ã¯å®è³ªçã«åå¿ã¯ãªãã
æ¬çºæã«ããååç©ã¯ãçµå£æäžåŸæ¯æ§ã瀺ã
ããè©Šéšããã©ã®æäžéã¬ãã«ã«ãããŠãæ»äº¡äŸ
ã¯ãªãã€ããããã«å¯ŸããŠã4â²âã¢ããã¡ãã«â
ïŒïŒ5â²âïŒâããªã¡ãã«ããœã©ã¬ã³ã¯ã匷ãçµå£
æäžæ¯æ§ã瀺ãã40mgïŒKgæäžåç©ã§å€æ°äŸã芳
å¯æéå ã«æ»äº¡ããæ¬ååç©ã®LD50å€ãããã®
æäžéã¬ãã«ããã¯ããã«å°ããããšãæãããš
ãªã€ãã
48æéã®æž¬å®ã§çŽ æ圢æ掻æ§ã瀺ãããããã¯çµ
å£æäžåŸ48æéã®æž¬å®ã§é¡èãªæŽ»æ§ã瀺ããå æ
åæ§ã®å¹åã®é«ã極倧ãéãããªäœçšçºçŸãªãã³
ã«æ¥éãªäœçšäœäžã䌎ãªããååç©5â²âã¢ããã¡
ãã«â4â²ïŒïŒïŒïŒâããªã¡ãã«ããœã©ã¬ã³ã¯ç¹ã«
é¡èã§ããã240ãè¶ããã€360åãŸã§æ°Žæ³¡åå¿ã
éããã«äœçšçºçŸãã30ã360åéæ倧å€ãä¿
ã¡ãå ã10åã§åŒ·ãçŽ æã®åæéå§æãæããŠã
ãã20mgïŒKgã§ã¯å ãã«æŽ»æ§ãå£ãã ãã§ã10
mgïŒKgã«ãããŠãããè¿ éãªåŒ·ãé·æéã®æŽ»æ§ã®
æå¹æ§ãæãããïŒâã¢ããã¡ãã«âïŒïŒ5â²âïŒ
âããªã¡ãã«ããœã©ã¬ã³ãšæ¯ã¹ããšãå æåæ§ã®
æ倧å€ãæ倧å€ãžã®éå§æããã³æ倧å€ã®ç¶ææ
éã®ç¹ã§ã¯ããã«åªããŠãããã®ã§ããããã®å
æåå¹æã¯ããŸã10mgïŒKgã®ïŒåã®ïŒã®çµå£æäž
ã§ãå šãŠã®é¢ã§åªãããã®ã§ãããããã«å¯Ÿã
ãŠã5â²âã¢ããã¡ãã«â4â²âã¡ãã«ããœã©ã¬ã³
ïŒïŒâããããã·ã¯ããªã³ãšåäžæ¹æ³ã§è£œé ïŒ
ã¯ã24æéããã³48æéã§ïŒïŒïŒïŒïŒã®å±æåå¿
ã瀺ããšã¯ãããçµå£ã§ã¯å®è³ªçã«åå¿ã¯ãªãã
æ¬çºæã«ããååç©ã¯ãçµå£æäžåŸæ¯æ§ã瀺ã
ããè©Šéšããã©ã®æäžéã¬ãã«ã«ãããŠãæ»äº¡äŸ
ã¯ãªãã€ããããã«å¯ŸããŠã4â²âã¢ããã¡ãã«â
ïŒïŒ5â²âïŒâããªã¡ãã«ããœã©ã¬ã³ã¯ã匷ãçµå£
æäžæ¯æ§ã瀺ãã40mgïŒKgæäžåç©ã§å€æ°äŸã芳
å¯æéå ã«æ»äº¡ããæ¬ååç©ã®LD50å€ãããã®
æäžéã¬ãã«ããã¯ããã«å°ããããšãæãããš
ãªã€ãã
æ¬çºæã®ååç©ã®çç©å
æå掻æ§ã¯
ïŒbiophotosensitization activtyïŒãã¿ã¯ããã³ã
ã€ãããããªãã¯ïŒPathak and FitzpatrickïŒ
èã€ã³ãŽãšã¹ãã»ããŒããã«ïŒInvest.Dermatol.
ïŒïŒç¬¬32å·»509ã518é ïŒ1959ïŒããã€ãªã¢ãã»ã€ã»
ãªãã»ãããŠã©ã«ã»ã¢ã³ãã»ã·ã³ã¹ãã€ãã¯ãã
ã¯ããªã³ãºïŒããœã©ã¬ã³ãºïŒïŒBioassayof
Natural and Synthetic Furocoumarins
ïŒPsoralensïŒãã®æäœããã³äžè¿°ãããããªéåžž
ã«é©çšãããæšæºçãªå€æŽã«åºã¥ãçŽ ææ§å¿çè©Š
éšã«ãããŠå®è³ªæ§ãæããããçç©çå æå掻
æ§ãã¯ãããã§ã¯ãåºä¹³åç©ã®ç®èãžã®å ååŠç
æåæ§ããšåæ§ã«çšãããããããŠãå ååŠç
æ³ããã§ããããæ¬çºæã®ååç©ã¯ãŸãä»ã®èŠ³ç¹
ãã掻æ§ãªçç©çå æåå€ãšããªããäœãšãªãã°
ãããã¯ãDNAå åå¿æ§ã®æšæºçãªè©Šéšã§æ©èœ
çè¿œå ç©ãçæããããã§ãããäŸãã°ããµã€ãš
ã³ã¹ïŒScienceïŒ1977ïŒ197ïŒ4306ïŒïŒ906ã908ïŒ
ãžã€ãŒãã«ã»ãªãã»ã¢ã¬ããŠã©ãŒã»ãã€ãªããžãŒ
ïŒïŒªã»Mol.Biol.ïŒ1977ïŒ116ïŒïŒïŒïŒ661ã679ïŒã
ã€ãªã±ãã¹ããªãŒïŒBiochemistrïŒ1977ïŒ16
ïŒïŒïŒïŒ1058ã1064ïŒããã³é¢é£æç®åç §ãããã
ãŠãæ¬ååç©ã¯æ žé žã®åå¿æ§ãäºæ¬¡çæ§é ã«é¢ã
ãç 究ã«ãããŠæçã§ãããRNAæš¡å
ïŒreplcationïŒã®ã€ã³ããã¿ãŒãšããŠæçã§ã
ãããã€PUVAæäœã«ãã也鮮ïŒpsoriasisïŒã®
å ååŠçæ³ã«ãããŠåæ§ã«ããŒã«ã¹ã®äžæŽ»æ§åã«
ãããŠãçšãããããšã瀺ãããããã®PUVAæ
äœã«ãããŠåŸæ¥çšããããå€ãã®ããœã©ã¬ã³åå
ç©é¡ãšåæ§ã«å¹æã®ããããšãèŠåºãããŠããã
ãããã®æå¹æ§ã¯ãã¡ããçš®ã ã®ãã¢ã¯ã¿ãŒãäŸ
ãã°ç §å°éãå æåå€ã®æçšéãé©çšæ¹æ³ïŒå±æ
çãšããçµå£çã«ãïŒããã³PUVAçæ³ã«é©çšã
ããåºä¹³åç©ïŒãã¡ãã人éãå«ãŸããïŒã®åå¥
çãªç®èã®æå床ãªã©ã«äŸåããããããŠãã®ä¹Ÿ
é®®ã¯äººéã«ãšã€ãŠã¯ãŠããŒã¯ãªç æ°ã§ããããã®
ååç©ã¯ããããŠäžè¿°ããç®çã«ãšã€ãŠæçãªã
ã®ã§ãããç¹ã«ãåºä¹³åç©ã®ç®èãžã®å åŠçæå
æ§ãæå¹ãããããããããã®è¡šçŸã¯ç®èäžãžã®
çŽ æãçæããããããšã«éå®ããããã®ã§ã¯ãª
ãããã§ããããããã¯çµå£çã«ãå±æçã«ãæ
å¹ã§ããããããŠåºä¹³åç©ç®èãžã®å åŠçæåæ§
ãæå¹ãããããæ¹æ³ã¯ããã æ¬çºæã®ååç©ã®
æå¹ãªå æåçšã®æäžéãåœè©²åºä¹³åç©ã«çµå£ç
ãªããå±æçã«é©çšããæäœã ãã§ããã被æ€è
ã玫å€ç §å°ãç¹ã«çŽ«å€ââã«ã€ã±ãããªãç¯å²
å ã§ããããããšããDNAã§ã®æ©èœçä»å ç©ã
圢æããã也鮮ã¯äžè¿°ããããã«äººäœæ£éšã«ãã
ãŠåãããããã®ã§ãããæ¬çºæã®ååç©ã®ä»ã®
çšéã¯äžè¿°ããããã«ããŠèŠåºãããã
ïŒbiophotosensitization activtyïŒãã¿ã¯ããã³ã
ã€ãããããªãã¯ïŒPathak and FitzpatrickïŒ
èã€ã³ãŽãšã¹ãã»ããŒããã«ïŒInvest.Dermatol.
ïŒïŒç¬¬32å·»509ã518é ïŒ1959ïŒããã€ãªã¢ãã»ã€ã»
ãªãã»ãããŠã©ã«ã»ã¢ã³ãã»ã·ã³ã¹ãã€ãã¯ãã
ã¯ããªã³ãºïŒããœã©ã¬ã³ãºïŒïŒBioassayof
Natural and Synthetic Furocoumarins
ïŒPsoralensïŒãã®æäœããã³äžè¿°ãããããªéåžž
ã«é©çšãããæšæºçãªå€æŽã«åºã¥ãçŽ ææ§å¿çè©Š
éšã«ãããŠå®è³ªæ§ãæããããçç©çå æå掻
æ§ãã¯ãããã§ã¯ãåºä¹³åç©ã®ç®èãžã®å ååŠç
æåæ§ããšåæ§ã«çšãããããããŠãå ååŠç
æ³ããã§ããããæ¬çºæã®ååç©ã¯ãŸãä»ã®èŠ³ç¹
ãã掻æ§ãªçç©çå æåå€ãšããªããäœãšãªãã°
ãããã¯ãDNAå åå¿æ§ã®æšæºçãªè©Šéšã§æ©èœ
çè¿œå ç©ãçæããããã§ãããäŸãã°ããµã€ãš
ã³ã¹ïŒScienceïŒ1977ïŒ197ïŒ4306ïŒïŒ906ã908ïŒ
ãžã€ãŒãã«ã»ãªãã»ã¢ã¬ããŠã©ãŒã»ãã€ãªããžãŒ
ïŒïŒªã»Mol.Biol.ïŒ1977ïŒ116ïŒïŒïŒïŒ661ã679ïŒã
ã€ãªã±ãã¹ããªãŒïŒBiochemistrïŒ1977ïŒ16
ïŒïŒïŒïŒ1058ã1064ïŒããã³é¢é£æç®åç §ãããã
ãŠãæ¬ååç©ã¯æ žé žã®åå¿æ§ãäºæ¬¡çæ§é ã«é¢ã
ãç 究ã«ãããŠæçã§ãããRNAæš¡å
ïŒreplcationïŒã®ã€ã³ããã¿ãŒãšããŠæçã§ã
ãããã€PUVAæäœã«ãã也鮮ïŒpsoriasisïŒã®
å ååŠçæ³ã«ãããŠåæ§ã«ããŒã«ã¹ã®äžæŽ»æ§åã«
ãããŠãçšãããããšã瀺ãããããã®PUVAæ
äœã«ãããŠåŸæ¥çšããããå€ãã®ããœã©ã¬ã³åå
ç©é¡ãšåæ§ã«å¹æã®ããããšãèŠåºãããŠããã
ãããã®æå¹æ§ã¯ãã¡ããçš®ã ã®ãã¢ã¯ã¿ãŒãäŸ
ãã°ç §å°éãå æåå€ã®æçšéãé©çšæ¹æ³ïŒå±æ
çãšããçµå£çã«ãïŒããã³PUVAçæ³ã«é©çšã
ããåºä¹³åç©ïŒãã¡ãã人éãå«ãŸããïŒã®åå¥
çãªç®èã®æå床ãªã©ã«äŸåããããããŠãã®ä¹Ÿ
é®®ã¯äººéã«ãšã€ãŠã¯ãŠããŒã¯ãªç æ°ã§ããããã®
ååç©ã¯ããããŠäžè¿°ããç®çã«ãšã€ãŠæçãªã
ã®ã§ãããç¹ã«ãåºä¹³åç©ã®ç®èãžã®å åŠçæå
æ§ãæå¹ãããããããããã®è¡šçŸã¯ç®èäžãžã®
çŽ æãçæããããããšã«éå®ããããã®ã§ã¯ãª
ãããã§ããããããã¯çµå£çã«ãå±æçã«ãæ
å¹ã§ããããããŠåºä¹³åç©ç®èãžã®å åŠçæåæ§
ãæå¹ãããããæ¹æ³ã¯ããã æ¬çºæã®ååç©ã®
æå¹ãªå æåçšã®æäžéãåœè©²åºä¹³åç©ã«çµå£ç
ãªããå±æçã«é©çšããæäœã ãã§ããã被æ€è
ã玫å€ç §å°ãç¹ã«çŽ«å€ââã«ã€ã±ãããªãç¯å²
å ã§ããããããšããDNAã§ã®æ©èœçä»å ç©ã
圢æããã也鮮ã¯äžè¿°ããããã«äººäœæ£éšã«ãã
ãŠåãããããã®ã§ãããæ¬çºæã®ååç©ã®ä»ã®
çšéã¯äžè¿°ããããã«ããŠèŠåºãããã
æ¬çºæã«ããè¬å€äžã®çµæç©ã¯åºä¹³åç©ã®ç®è
ãšãã«äººéæ£è ã被æ€è ãžã®å ååŠçæåæ§ãæ
å¹ãããããããã«å¥œé©ã«çšããããããããŠè¬
å€åŠäžåãå ¥ãããŠãããã€ãªã€ãŒãåžéå€ãšãš
ãã«æ¬çºæã®ååç©ãæå¹éå«æããããŠãªãã
ã®ã§ããããã®ãããªçµæç©ã¯åœæ¥çã§ã¯å ¬ç¥ã®
ãã®ã§ãããåèäŸãšããŠã¯ç±³åœç¹èš±ç¬¬4124598
å·ããã³ç¬¬4130568å·ã«ãããŠä»£è¡šçãªäŸç€ºãå
æ§ãªé瀺ãããããã®çµæç©ã調補ããããã®æ¹
æ³ã¯ãå šãŠåœæ¥çã§éåžžã®ãã®ã§ããã也鮮ã®çµ
å£çåŠçã®ããã«ã¯ã掻æ§ãªæåã¯äžè¬ã«ã¿ãã¬
ããããŒã©ãã³ã«ãã»ã«ã«èª¿åãããããã®å Ž
åãåžéå€ã¯ææãªãã°äžèŠã§ããããäžè¬ã«ã¯
å ããããããå±æãžã®é©çšã«å¯ŸããŠã¯ã溶液ãŸ
ãã¯è»èã調補ãããŠé©çšãããã§ãããããã
ãã¯è¬å€åŠäžåå ¥ãããããæ°å€ãã®ãã€ãªã€ãš
ãšãã«å ¬ç¥ã®æ¹æ³ã§èª¿åããããæœè¬ã¯ãäŸãã°
ã¿ãã¬ãããã«ãã»ã«ãç²æ«ãã·ããããŸãã¯æº¶
液ã®åœ¢ã§ãã§ã«è¿°ã¹ãè»èãã¯ãªãŒã ã溶液ãšã
ã€ãå±æé©çšæ§ã®ãã®ãšåæ§ã«ããŠãªããããã¿
ãã¬ãã調åãšããŠã¯ãéåžžã®ã¿ãã¬ããã¢ãžãŠ
ãã³ããäŸãã°ã³ãŒã³ã¹ã¿ãŒãããããã¹ã¿ãŒ
ããã¿ã«ã«ã ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ããŒã©
ãã³ãã©ã¯ããŒã¹ãã¬ã çã䜿çšãããããŸãã
ä»ã®è¬å€åŠçã«ã¿ãã¬ããã«ãåŸãã¢ãžãŠãã³ã
ã䜿çšãåŸãããã¡ãã掻æ§ãªæåãšäž¡ç«ããã
ãã®ã§ãªããã°ãªããªããäžè¬ã«ãçµå£çãªæäž
éé€çæ³ã§ã¯äœéKgåœãïŒmgãã50mgãå«ããã®
ã§ãäžè¬ã«ã¯KgåœãçŽïŒã10mgã®è¿èŸºã®æäžéã
奜ãŸããããã®ãããªæœè¬ããã³æäžéããã³å
äœæäžéã®éžæã¯ããã¡ããã確ç«ãããå»åŠäž
ã®ååã«ãããã€ãŠããã€PUVAçæ³ã«åœããå»
è ã®æå³ã®äžã«æ±ºå®ãããã°ãªããªããå±æçšã«
çšãããšãã«ã¯ãåäœé¢ç©åœåãæå¹ãªæŽ»æ§æå
éã®ã¿ãå«ãŸããããã«ããå ·äœçã«ã¯ãããã¯
ïŒïŒ 溶液ãæžæ¿æ¶²ãªããè»èã®åœ¢ã§ãããããå ·
äœçã«ã¯å¹³æ¹ã»ã³ãã¡ãŒãã«åœã10åã®ïŒããªãª
ããã«ã®ç¯å²ã§ãããé©åœãªãã€ãªã€âäŸãã°ã
ãšã¿ããŒã«ãªãããã§ã«è¿°ã¹ãä»ã®ã¿ã€ãã®ãã€
ãªã€ãŒãšäœµçšããã
ãšãã«äººéæ£è ã被æ€è ãžã®å ååŠçæåæ§ãæ
å¹ãããããããã«å¥œé©ã«çšããããããããŠè¬
å€åŠäžåãå ¥ãããŠãããã€ãªã€ãŒãåžéå€ãšãš
ãã«æ¬çºæã®ååç©ãæå¹éå«æããããŠãªãã
ã®ã§ããããã®ãããªçµæç©ã¯åœæ¥çã§ã¯å ¬ç¥ã®
ãã®ã§ãããåèäŸãšããŠã¯ç±³åœç¹èš±ç¬¬4124598
å·ããã³ç¬¬4130568å·ã«ãããŠä»£è¡šçãªäŸç€ºãå
æ§ãªé瀺ãããããã®çµæç©ã調補ããããã®æ¹
æ³ã¯ãå šãŠåœæ¥çã§éåžžã®ãã®ã§ããã也鮮ã®çµ
å£çåŠçã®ããã«ã¯ã掻æ§ãªæåã¯äžè¬ã«ã¿ãã¬
ããããŒã©ãã³ã«ãã»ã«ã«èª¿åãããããã®å Ž
åãåžéå€ã¯ææãªãã°äžèŠã§ããããäžè¬ã«ã¯
å ããããããå±æãžã®é©çšã«å¯ŸããŠã¯ã溶液ãŸ
ãã¯è»èã調補ãããŠé©çšãããã§ãããããã
ãã¯è¬å€åŠäžåå ¥ãããããæ°å€ãã®ãã€ãªã€ãš
ãšãã«å ¬ç¥ã®æ¹æ³ã§èª¿åããããæœè¬ã¯ãäŸãã°
ã¿ãã¬ãããã«ãã»ã«ãç²æ«ãã·ããããŸãã¯æº¶
液ã®åœ¢ã§ãã§ã«è¿°ã¹ãè»èãã¯ãªãŒã ã溶液ãšã
ã€ãå±æé©çšæ§ã®ãã®ãšåæ§ã«ããŠãªããããã¿
ãã¬ãã調åãšããŠã¯ãéåžžã®ã¿ãã¬ããã¢ãžãŠ
ãã³ããäŸãã°ã³ãŒã³ã¹ã¿ãŒãããããã¹ã¿ãŒ
ããã¿ã«ã«ã ãã¹ãã¢ãªã³é žãã°ãã·ãŠã ããŒã©
ãã³ãã©ã¯ããŒã¹ãã¬ã çã䜿çšãããããŸãã
ä»ã®è¬å€åŠçã«ã¿ãã¬ããã«ãåŸãã¢ãžãŠãã³ã
ã䜿çšãåŸãããã¡ãã掻æ§ãªæåãšäž¡ç«ããã
ãã®ã§ãªããã°ãªããªããäžè¬ã«ãçµå£çãªæäž
éé€çæ³ã§ã¯äœéKgåœãïŒmgãã50mgãå«ããã®
ã§ãäžè¬ã«ã¯KgåœãçŽïŒã10mgã®è¿èŸºã®æäžéã
奜ãŸããããã®ãããªæœè¬ããã³æäžéããã³å
äœæäžéã®éžæã¯ããã¡ããã確ç«ãããå»åŠäž
ã®ååã«ãããã€ãŠããã€PUVAçæ³ã«åœããå»
è ã®æå³ã®äžã«æ±ºå®ãããã°ãªããªããå±æçšã«
çšãããšãã«ã¯ãåäœé¢ç©åœåãæå¹ãªæŽ»æ§æå
éã®ã¿ãå«ãŸããããã«ããå ·äœçã«ã¯ãããã¯
ïŒïŒ 溶液ãæžæ¿æ¶²ãªããè»èã®åœ¢ã§ãããããå ·
äœçã«ã¯å¹³æ¹ã»ã³ãã¡ãŒãã«åœã10åã®ïŒããªãª
ããã«ã®ç¯å²ã§ãããé©åœãªãã€ãªã€âäŸãã°ã
ãšã¿ããŒã«ãªãããã§ã«è¿°ã¹ãä»ã®ã¿ã€ãã®ãã€
ãªã€ãŒãšäœµçšããã
æ¬çºæã®ã¢ãã³é¡ã¯ãã®è¬å€åŠäžåå
¥ãããã
é žã®ä»å å¡©ã®åœ¢ã§äŸ¿å©ã«çšãããããæ¬çºæã®å
åç©ãé žä»å å¡©ã®åœ¢ã§åé¢ãããšãã«ã¯ãå°ãªã
ãšãæ²»çäžã®æçšã«ãããŠéæ¯æ§ã§ãããè¬å€åŠ
äžåå ¥ããããé°ã€ãªã³ãå«ããããªãã®ã®äžã
ãéžã°ããã奜ãŸããã°ã«ãŒãã«å«ãŸãã代衚ç
ãªå¡©ã¯ãéçé žå¡©ãå¡©é žå¡©ãèåæ°ŽçŽ é žå¡©ãç¡«é ž
å¡©ãé ¢é žå¡©ããªã³é žå¡©ãç¡é žå¡©ãã¡ã¿ã³ã¹ã«ãã³
é žå¡©ããšã¿ã³ã¹ã«ãã³é žå¡©ãä¹³é žå¡©ãã¯ãšã³é ž
å¡©ãé ç³é žå¡©ãªããéé ç³é žå¡©ããã³ãã¬ã€ã³é ž
å¡©ã§ãããä»ã®é žãåæ§ã«é©çšãããææãªãã°
çšããããäŸãã°ããã¿ã«é žãå®æ¯éŠé žãã¢ã¹ã³
ã«ãã³é žãã³ãã¯é žããµã«ãã«é žããã¹ã¡ãã¬ã³
ãµãªãã«é žãããããªã³é žãã°ã«ã³ã³é žããªã³ãŽ
é žããã³é žããã³ãã«é žãæ¡ç®é žãã·ãã©ã³ã³
é žãã¹ãã¢ãªã³é žããã«ããã³é žãã€ã¿ã³ã³é žã
ã°ã«ã³ãŒã«é žããã³ãŒã³ã¹ã«ãã³é žããã³ã¹ã«ã
ã¢ãã³é žãé žä»å 塩圢æçšé žãšããŠçšãåŸãã
é žã®ä»å å¡©ã®åœ¢ã§äŸ¿å©ã«çšãããããæ¬çºæã®å
åç©ãé žä»å å¡©ã®åœ¢ã§åé¢ãããšãã«ã¯ãå°ãªã
ãšãæ²»çäžã®æçšã«ãããŠéæ¯æ§ã§ãããè¬å€åŠ
äžåå ¥ããããé°ã€ãªã³ãå«ããããªãã®ã®äžã
ãéžã°ããã奜ãŸããã°ã«ãŒãã«å«ãŸãã代衚ç
ãªå¡©ã¯ãéçé žå¡©ãå¡©é žå¡©ãèåæ°ŽçŽ é žå¡©ãç¡«é ž
å¡©ãé ¢é žå¡©ããªã³é žå¡©ãç¡é žå¡©ãã¡ã¿ã³ã¹ã«ãã³
é žå¡©ããšã¿ã³ã¹ã«ãã³é žå¡©ãä¹³é žå¡©ãã¯ãšã³é ž
å¡©ãé ç³é žå¡©ãªããéé ç³é žå¡©ããã³ãã¬ã€ã³é ž
å¡©ã§ãããä»ã®é žãåæ§ã«é©çšãããææãªãã°
çšããããäŸãã°ããã¿ã«é žãå®æ¯éŠé žãã¢ã¹ã³
ã«ãã³é žãã³ãã¯é žããµã«ãã«é žããã¹ã¡ãã¬ã³
ãµãªãã«é žãããããªã³é žãã°ã«ã³ã³é žããªã³ãŽ
é žããã³é žããã³ãã«é žãæ¡ç®é žãã·ãã©ã³ã³
é žãã¹ãã¢ãªã³é žããã«ããã³é žãã€ã¿ã³ã³é žã
ã°ã«ã³ãŒã«é žããã³ãŒã³ã¹ã«ãã³é žããã³ã¹ã«ã
ã¢ãã³é žãé žä»å 塩圢æçšé žãšããŠçšãåŸãã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ 5â²â第äžçŽã¢ããäœçŽã¢ã«ãã«â4â²ïŒïŒïŒïŒ
âããªäœçŽã¢ã«ãã«ããœã©ã¬ã³ã ïŒ 5â²âã¢ããã¡ãã«â4â²ïŒïŒïŒïŒâããªã¡ãã«
ããœã©ã¬ã³ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®
ååç©ã ïŒ 5â²âã€ããäœçŽã¢ã«ãã«â4â²ïŒïŒïŒïŒâããª
äœçŽã¢ã«ãã«ããœã©ã¬ã³ãããã©ãžããªã·ã¹ã«äŸ
ããŠå¯Ÿå¿ãã5â²â第äžçŽã¢ããäœçŽã¢ã«ãã«â
4â²ïŒïŒïŒïŒâããªäœçŽã¢ã«ãã«ããœã©ã¬ã³ã補é
ããå·¥çšãããªã5â²â第äžçŽã¢ããäœçŽã¢ã«ãã«
â4â²ïŒïŒïŒïŒâããªäœçŽã¢ã«ãã«ããœã©ã¬ã³ã®è£œ
é æ¹æ³ã ïŒ åºçºç©è³ªã5â²âã€ããã¡ãã«â4â²ïŒïŒïŒïŒâ
ããªäœçŽã¢ã«ãã«ããœã©ã¬ã³ã§ããããã€çæç©
ã5â²âã¢ããã¡ãã«â4â²ïŒïŒïŒïŒâããªäœçŽã¢ã«
ãã«ããœã©ã¬ã³ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èš
èŒã®æ¹æ³ã ïŒ åºçºç©è³ªã5â²âãã¿ã«ã€ããã¡ãã«â4â²ïŒ
ïŒïŒïŒâããªã¡ãã«ããœã©ã¬ã³ã§ããããã€çæ
ç©ã5â²âã¢ããã¡ãã«â4â²ïŒïŒïŒïŒâããªã¡ãã«
ããœã©ã¬ã³ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã«èšèŒã®
æ¹æ³ã
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/173,437 US4294822A (en) | 1980-07-29 | 1980-07-29 | 5-Aminoalkyl-4,4,8-trialkylpsoralens |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5753490A JPS5753490A (en) | 1982-03-30 |
JPS621952B2 true JPS621952B2 (ja) | 1987-01-16 |
Family
ID=22632020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56117870A Granted JPS5753490A (en) | 1980-07-29 | 1981-07-29 | 5'-aminoalkyl-4',4,8-trialkylpsoralens |
Country Status (6)
Country | Link |
---|---|
US (1) | US4294822A (ja) |
JP (1) | JPS5753490A (ja) |
CA (1) | CA1158251A (ja) |
DE (1) | DE3129750A1 (ja) |
FR (1) | FR2495154B1 (ja) |
GB (1) | GB2080806B (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4950770A (en) * | 1987-06-16 | 1990-08-21 | Elder Pharmaceuticals, Inc. | Psoralens aminomethylation |
US5356929A (en) * | 1989-01-23 | 1994-10-18 | Lehigh University | Reduced and quaternized psoralens as photo-activated therapeutics |
US5216176A (en) * | 1989-01-23 | 1993-06-01 | Lehigh University | 7-alkoxycoumarins, dihydropsoralens, and benzodipyranones as photo-activated therapeutic agents and inhibitors of epidermal growth factor |
WO1991006665A1 (en) * | 1989-10-26 | 1991-05-16 | Isaacs Stephen T | Activation compounds and methods for nucleic acid sterilization |
US5556958A (en) * | 1989-10-26 | 1996-09-17 | Steritech, Inc. | Inactivation of pathogens in clinical samples |
US5116864A (en) * | 1991-04-09 | 1992-05-26 | Indiana University Foundation | Method for preventing restenosis following reconfiguration of body vessels |
AU6402494A (en) * | 1993-03-11 | 1994-09-26 | Steritech, Inc. | Decontaminating clinical samples |
US5593823A (en) * | 1993-06-28 | 1997-01-14 | Cerus Corporation | Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens |
US5399719A (en) * | 1993-06-28 | 1995-03-21 | Steritech, Inc. | Compounds for the photodecontamination of pathogens in blood |
US6420570B1 (en) | 1993-06-28 | 2002-07-16 | Cerus Corporation | Psoralen compounds |
US5556993A (en) | 1993-06-28 | 1996-09-17 | Steritech, Inc. | Compounds for the photodecontamination of pathogens in blood |
US6004742A (en) * | 1993-06-28 | 1999-12-21 | Cerus Corporation | Method for inactivation of pathogens in platelets using 4' and 5' primary amino-substituted psoralens |
US5871900A (en) * | 1993-06-28 | 1999-02-16 | Cerus Corporation | Method of inactivating pathogens in biological fluids using photoactivated 5-primaryamino psoralens |
US6004741A (en) * | 1993-06-28 | 1999-12-21 | Cerus Corporation | Method for the photoactivation of 4' and 5' primary aminoalkyl psoralens in platelet preparations |
US5691132A (en) | 1994-11-14 | 1997-11-25 | Cerus Corporation | Method for inactivating pathogens in red cell compositions using quinacrine mustard |
US5663043A (en) * | 1995-01-04 | 1997-09-02 | Hemasure Inc. | Method for inactivating non-enveloped viruses using a viricide-potentiating agent with a photoactivatible virucide |
US6177441B1 (en) | 1995-06-05 | 2001-01-23 | Cerus Corporation | Treating red blood cell solutions with anti-viral agents |
US20020115585A1 (en) * | 1996-06-07 | 2002-08-22 | Hei Derek J. | Method and devices for the removal of psoralens from blood products |
DE69819360T2 (de) * | 1997-11-20 | 2004-08-19 | Cerus Corp., Concord | Neue psoralene zur inaktivierung von pathogenen |
US6255324B1 (en) | 1998-11-25 | 2001-07-03 | Ned D. Heindel | Amino-and mercurio-substituted 4â²,5'-dihydropsoralens and therapeutical uses thereof |
ATE223418T1 (de) | 1998-11-30 | 2002-09-15 | Buckman Labor Inc | 4'-substituierte-4',5'-dihydropsoralene und deren therapeutische verwendung |
FR2803849B1 (fr) * | 2000-01-19 | 2002-04-19 | Centre Nat Rech Scient | Molecules chimeres formees de psoralene et de retinoide, leur procede de preparation, et leurs applications au traitement de pathologies de l'hyperproliferation cellulaire et notamment du psoriasis |
WO2015195896A1 (en) * | 2014-06-19 | 2015-12-23 | Immunolight, Llc | Methods and systems for treating cell proliferation disorders with psoralen derivatives |
US8071642B2 (en) * | 2007-06-28 | 2011-12-06 | Rutgers, The State University Of New Jersey | Dimethyl amino ethyl ether psoralens and methods for their production and use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4169204A (en) * | 1976-10-20 | 1979-09-25 | Regents Of The University Of California | Psoralens |
US4124598A (en) * | 1976-10-20 | 1978-11-07 | Hoffmann-La Roche Inc. | Psoralens |
US4298614A (en) * | 1979-09-10 | 1981-11-03 | Thomas C. Elder, Inc. | 5'-Aminoalkyl-4',4-dialkylpsoralens |
-
1980
- 1980-07-29 US US06/173,437 patent/US4294822A/en not_active Expired - Lifetime
-
1981
- 1981-07-27 GB GB8123060A patent/GB2080806B/en not_active Expired
- 1981-07-28 CA CA000382640A patent/CA1158251A/en not_active Expired
- 1981-07-28 DE DE19813129750 patent/DE3129750A1/de not_active Withdrawn
- 1981-07-29 JP JP56117870A patent/JPS5753490A/ja active Granted
- 1981-07-29 FR FR8114749A patent/FR2495154B1/fr not_active Expired
Also Published As
Publication number | Publication date |
---|---|
FR2495154A1 (fr) | 1982-06-04 |
FR2495154B1 (fr) | 1985-06-28 |
US4294822A (en) | 1981-10-13 |
CA1158251A (en) | 1983-12-06 |
GB2080806A (en) | 1982-02-10 |
JPS5753490A (en) | 1982-03-30 |
DE3129750A1 (de) | 1982-03-18 |
GB2080806B (en) | 1984-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS621952B2 (ja) | ||
US5032617A (en) | Substituted benzamide radiosensitizers | |
IE51692B1 (en) | Furocoumarin compositions | |
JPH04503212A (ja) | ïŒâãªããã·ã²ããŒãŒé»æ¢å€ãšããŠã®ïŒâããããã·ãã¢ãŸãŒã« | |
JPH11503457A (ja) | åºä¹³é¡ã«ãããçããã³ãŠã£ã«ã¹ã®æé·ãé»æ¢ããïœâã¯ãããã§ãã«ã«ã«ãã¡ãŒããïœâã¯ãããã§ãã«ããªã«ã«ãã¡ãŒãããã³ïœâãã¹ããã°ãªã·ã³èªå°äœãå«æããå»è¬çµæç© | |
US4298614A (en) | 5'-Aminoalkyl-4',4-dialkylpsoralens | |
US4269852A (en) | 4'-Substituted-4,5',8-trialkylpsoralens | |
US4370344A (en) | 5'-Aminoalkyl-4'-alkylpsoralens | |
JPH06505475A (ja) | å ååŠççæ³ã«çŽæ¥å©çšãããããŸãã¯å ååŠççæ³ã«é©åãªå 掻æ§è²çŽ ã®åæäžéäœãšããŠå©çšãããã«ãã£ã»ã³èªå°äœ | |
US4269851A (en) | 8-Aminoalkyl-4-alkylpsoralens | |
US4294847A (en) | 8-Aminoalkyl-4-alkylisopsoralens | |
US4328239A (en) | 8-Aminoalkylpsoralens | |
JP3070767B2 (ja) | æè «çåã³æâã¬ãããŠã£ã«ã¹å€ãšããŠæçšãªã¢ããã·ã³ãžãã¹ããªããŒã¹ããªã¡ã©ãŒãŒçµåæ§ããããœè³éŠæååç© | |
US4279922A (en) | Photosensitizing benzofuranacrylics | |
Koo | Communications. New Classes of Active Central Nervous System Depressing and Stimulating Agents. | |
US3767674A (en) | Cyclohexeno thioxanthones | |
Collier et al. | Antifungal activities of bisisoquinolinium and bisquinolinium salts | |
JP7223842B2 (ja) | éžæçïœïŒïœå容äœã¢ã³ã¿ãŽãã¹ã | |
NO165635B (no) | Analogifremgangsmaate for fremstilling av nye terapeutisk aktive kinolinderivater. | |
US4755516A (en) | Antiviral compounds | |
JP2511709B2 (ja) | ããµã³ãã·ãªã³ïœã¢ãã¡ãã«ãšâãã«èªå°äœåã³ãããå«æããæè «çå€ | |
JP2897310B2 (ja) | ãããŸãªã³èªå°äœããã³ãã®å¡© | |
DE69006187T2 (de) | Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der AnsteckungsfÀhigkeit von mit Glykoproteinen umhÌllten Viren. | |
JPS62158274A (ja) | 眮æâïŒïŒïŒâãžããšã¿ã³èªå°äœ | |
JPH0665668B2 (ja) | ããšãã«ãã©ãžã³èªå°äœããã³æè¡æ å€ |